Abstract 5540: Preclinical investigation of the novel histone deacetylase (HDAC) inhibitor AR-42 in the treatment of cancer-induced cachexia
Authors: Yu-Chou Tseng, Samuel Kulp, I-Lu Lai, Wei He, Ralf Bundschuh, David Frankhouser, Pearlly Yan, Denis Guttridge, Guido Marcucci, Ching-Shih Chen, Tanios Bekaii-Saab
Journal: Cancer Research (2014)

Abstract Background: Cachexia occurs in more than 50% of cancer patients. Cachexia is characterized by severe loss of weight and skeletal muscle that is not reversed by nutritional support, and contributes significantly to morbidity and mortality. The development of effective therapies for cancer cachexia is clearly warranted. AR-42 is a novel class I/IIB HDAC inhibitor that was developed in our laboratories and currently in Phase I/IB trials at The Ohio State University. Here, we report the anti-cachectic activity of AR-42 in two murine models of cancer cachexia. Methods: Experiments were conducted using the colon-26 adenocarcinoma (C-26) and Lewis lung carcinoma (LLC) tumor mice models of cancer cachexia. AR-42 was administered by oral gavage at 50 mg/kg every other day starting at day 6 after tumor cell inoculation. Serum samples (n = 3) and muscle tissues (n = 8) from each group were sent for RNAseq and small RNAseq (OSU), cytokine/chemokine profiling assays [Eve Technologies, Alberta, Canada] and metabolomic analyses [Metabolon, Research Triangle Park, NC]. Results: In the C-26 model, AR-42 significantly attenuated cachexia-induced losses of skeletal muscle mass and body weight, with minimal effects on C-26 tumor growth, and prolonged survival time relative to mice treated with vehicle only or with other HDAC inhibitors (vorinostat and romidepsin). Metabolomic and gene expression analyses revealed that the effects of AR-42 were associated with its ability to maintain metabolic and gene expression profiles in skeletal muscle to levels comparable to those in muscle from tumor-free mice. Analysis of RNAseq data of relevant genes suggests that AR-42 modulates major pathways involved in muscle wasting, mitochondrial function, lipolysis, and cytoskeletal integrity. The main mechanism of action is thought to be through down-regulating FOXO1 (&amp;gt; 5-fold) leading to suppression of MuRF1 and Atrogin-1. Additional mechanistic validation is underway and full results will be available at the meeting. AR-42-induced abrogation of cachexia and rescue of muscle weight was additionally confirmed in the LLC model. Conclusion: Our results suggest AR-42 induces unique protective effects on cancer-induced muscle wasting and lipolysis, and our findings support further evaluation of AR-42 as a potential treatment for cancer cachexia. Citation Format: Yu-Chou Tseng, Samuel Kulp, I-Lu Lai, Wei He, Ralf Bundschuh, David Frankhouser, Pearlly Yan, Denis Guttridge, Guido Marcucci, Ching-Shih Chen, Tanios Bekaii-Saab. Preclinical investigation of the novel histone deacetylase (HDAC) inhibitor AR-42 in the treatment of cancer-induced cachexia. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5540. doi:10.1158/1538-7445.AM2014-5540